Pills masthead

News Releases

Archives: Search / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013

20122011201020092008200720062004

2019 Archives

May 6, 2019
- Net Sales, Excluding Levothyroxine, Continues Sequential Quarterly Growth

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 third quarter ended March 31, 2019. "Our solid third quarter financial results reflect continued growth of...

More
Apr 30, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54...

More
Apr 29, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 third quarter on Monday, May 6, 2019, after the market closes. Lannett management will...

More
Mar 27, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Aspirin and...

More
Mar 21, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.2 million principal amount of its Term Loans in open market transactions. The purchases...

More
Mar 11, 2019
--Company Expects to Commence Marketing the Product Near Term--

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Elite Pharmaceuticals and SunGen Pharma to be the exclusive U.S. distributor of a generic version of...

More
Feb 26, 2019

Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences. Schedule below: Raymond James 40th Annual Institutional Investors Conference at 1:05 p.m....

More
Feb 6, 2019
- Recent 17 Product Launches Contributed $40 Million of Net Sales in Fiscal 2019 YTD

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 second quarter ended December 31, 2018. "Stellar sales across our product offering drove our strong fiscal...

More
Feb 6, 2019
Product Launches, Cost Savings, Insulin Glargine
Jan 30, 2019

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes. Lannett...

More
Jan 22, 2019
Company Has Begun Marketing Entacapone IR Tablets

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules,...

More
 
Price Data
NYSELCI